Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

Transcriptional responses to direct and indirect TGFB1 stimulation in cancerous and noncancerous mammary epithelial cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.

TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis

Metabolic Reprogramming of Mammary Epithelial Cells during TGF--Induced Epithelial-to-Mesenchymal Transition

TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology.

Transcriptional regulators ensuring specific gene expression and decision-making at high TGF{beta} doses

Transcriptional regulators ensuring specific gene expression and decision making at high TGFβ doses

TGFβ Selects for Pro‐stemness over Pro‐invasive Phenotypes During Cancer Cell Epithelial–mesenchymal Transition

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

Role of glycosylation in TGF-β signaling and epithelial-to-mesenchymal transition in cancer

Visualizing Dynamic Changes During TGF-β-Induced Epithelial to Mesenchymal Transition.

TGF-β stimulation in human and murine cells reveals commonly affected biological processes and pathways at transcription level

Tgf-Beta Signaling In Breast Cancer Cell Invasion And Bone Metastasis

TGF-β Signaling in Breast Cancer Cell Invasion and Bone Metastasis

Epigenetic Reprogramming of TGF-β Signaling in Breast Cancer

Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor β

Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?

TGF-β1 Signaling Targets Metastasis-Associated Protein 1, a New Effector in Epithelial Cells.

TGF-β1 Induces HMGA1 Expression in Human Breast Cancer Cells: Implications of the Involvement of HMGA1 in TGF-β Signaling

Attenuated TGFB signalling in macrophages decreases susceptibility to DMBA-induced mammary cancer in mice

Transforming Growth Factor-Β1 Induces Epithelial-to-mesenchymal Transition and Promotes Abtaining of Stemness Characteristics in Gastric Cancer